Table 4.
Outcomes after neoadjuvant chemotherapy and liver resection (n= 50)
| Overall | Strong | Weak | P-value | |
|---|---|---|---|---|
| Outcomes | ||||
| Recurrence, n | 36 | 9 | 27 | 0.031 |
| Death, n | 16 | 2 | 14 | 0.029 |
| Site of recurrent disease | ||||
| Liver | 20 | 4 | 16 | |
| Lung | 15 | 5 | 10 | |
| Peritoneal/pelvic/retroperitoneal | 10 | 2 | 8 | |
| Skin/abdominal wall | 3 | 1 | 2 | |
| Bone | 5 | 0 | 5 | |
| Brain | 3 | 0 | 3 | |
| Adjuvant chemotherapy | ||||
| FOLFIRI | 24 | 10 | 14 | |
| FOLFOX | 15 | 5 | 10 | |
| 5FU/capecitabine | 12 | 4 | 8 | |
| Other | 5 | 2 | 3 | |
| Received multiple regimens, n | 23 | 12 | 11 | |
| Total number of cycles, mean | 12 | 13 | 12 | |
| Adjuvant therapies | ||||
| Radiofrequency ablation | 3 | 2 | 1 | |
| Hepatic arterial embolization | 4 | 2 | 2 | |
| Hepatic artery pump | 2 | 1 | 1 | |
| Radio-bead embolization | 3 | 1 | 2 | |
| External beam radiation | 1 | 0 | 1 | |
| Complete resection of recurrence | 6 | 1 | 5 |